中国糖尿病杂志
中國糖尿病雜誌
중국당뇨병잡지
CHINESE JOURNAL OF DIABETES
2002年
5期
276-279
,共4页
张吉吉%于德民%赵伟%李淑颖
張吉吉%于德民%趙偉%李淑穎
장길길%우덕민%조위%리숙영
前列地尔%尿蛋白和尿白蛋白%糖尿病肾病
前列地爾%尿蛋白和尿白蛋白%糖尿病腎病
전렬지이%뇨단백화뇨백단백%당뇨병신병
Prostaglandin E1%Proteinuria% Albuminuria% Diabetic nephropathy
目的观察短期应用静脉推注前列地尔( prostaglandin E1)对不同时期糖尿病肾病患者肾功能及尿蛋白的影响. 方法糖尿病肾病患者81例,年龄40～81岁;男45例,女36例.分为治疗组 45例和对照组36例.两组患者均根据尿蛋白和肾功能的不同再分别分为早期肾病组、临床期肾功能正常组和临床期肾功能不全组3个亚组.治疗组静脉推注前列地尔(商品名:凯时)10μg,每日一次,连续14 d.对照组不给上述治疗.控制血压、血脂、血糖等其他治疗方法各组相同. 结果和对照组比较,治疗组患者尿总蛋白和尿白蛋白明显降低,其中糖尿病肾病早期组尿总蛋白由治疗前的(0.34±0.06) g/24 h下降到(0.21±0.07)g/24 h(P<0.01),尿白蛋白由(191±76) mg/24 h下降到(99±53) mg/24 h(P<0.01);在临床期肾功能正常组尿总蛋白由(3.74±1.99) g/24 h下降到(2.38±1.47)g/24 h(P<0.01),尿白蛋白由(2 855±1 790) mg/24 h下降到(1 634±1 093)mg/24 h(P<0.01);在临床期肾功能不全组尿总蛋白由治疗前的(1.89±0.93) g/24 h下降到(1.84±1.08)g/24 h(P>0.05),尿白蛋白由(1 407±835) mg/24 h下降到(1 116±557)mg/24 h(P<0.05).治疗后6个月随访结果显示,治疗组3组患者尿蛋白水平无明显变化. 结论短期静脉应用前列地尔治疗,对不同时期的糖尿病肾病患者均有减少尿蛋白的作用,用药后6个月随访尿蛋白无明显回升.
目的觀察短期應用靜脈推註前列地爾( prostaglandin E1)對不同時期糖尿病腎病患者腎功能及尿蛋白的影響. 方法糖尿病腎病患者81例,年齡40～81歲;男45例,女36例.分為治療組 45例和對照組36例.兩組患者均根據尿蛋白和腎功能的不同再分彆分為早期腎病組、臨床期腎功能正常組和臨床期腎功能不全組3箇亞組.治療組靜脈推註前列地爾(商品名:凱時)10μg,每日一次,連續14 d.對照組不給上述治療.控製血壓、血脂、血糖等其他治療方法各組相同. 結果和對照組比較,治療組患者尿總蛋白和尿白蛋白明顯降低,其中糖尿病腎病早期組尿總蛋白由治療前的(0.34±0.06) g/24 h下降到(0.21±0.07)g/24 h(P<0.01),尿白蛋白由(191±76) mg/24 h下降到(99±53) mg/24 h(P<0.01);在臨床期腎功能正常組尿總蛋白由(3.74±1.99) g/24 h下降到(2.38±1.47)g/24 h(P<0.01),尿白蛋白由(2 855±1 790) mg/24 h下降到(1 634±1 093)mg/24 h(P<0.01);在臨床期腎功能不全組尿總蛋白由治療前的(1.89±0.93) g/24 h下降到(1.84±1.08)g/24 h(P>0.05),尿白蛋白由(1 407±835) mg/24 h下降到(1 116±557)mg/24 h(P<0.05).治療後6箇月隨訪結果顯示,治療組3組患者尿蛋白水平無明顯變化. 結論短期靜脈應用前列地爾治療,對不同時期的糖尿病腎病患者均有減少尿蛋白的作用,用藥後6箇月隨訪尿蛋白無明顯迴升.
목적관찰단기응용정맥추주전렬지이( prostaglandin E1)대불동시기당뇨병신병환자신공능급뇨단백적영향. 방법당뇨병신병환자81례,년령40～81세;남45례,녀36례.분위치료조 45례화대조조36례.량조환자균근거뇨단백화신공능적불동재분별분위조기신병조、림상기신공능정상조화림상기신공능불전조3개아조.치료조정맥추주전렬지이(상품명:개시)10μg,매일일차,련속14 d.대조조불급상술치료.공제혈압、혈지、혈당등기타치료방법각조상동. 결과화대조조비교,치료조환자뇨총단백화뇨백단백명현강저,기중당뇨병신병조기조뇨총단백유치료전적(0.34±0.06) g/24 h하강도(0.21±0.07)g/24 h(P<0.01),뇨백단백유(191±76) mg/24 h하강도(99±53) mg/24 h(P<0.01);재림상기신공능정상조뇨총단백유(3.74±1.99) g/24 h하강도(2.38±1.47)g/24 h(P<0.01),뇨백단백유(2 855±1 790) mg/24 h하강도(1 634±1 093)mg/24 h(P<0.01);재림상기신공능불전조뇨총단백유치료전적(1.89±0.93) g/24 h하강도(1.84±1.08)g/24 h(P>0.05),뇨백단백유(1 407±835) mg/24 h하강도(1 116±557)mg/24 h(P<0.05).치료후6개월수방결과현시,치료조3조환자뇨단백수평무명현변화. 결론단기정맥응용전렬지이치료,대불동시기적당뇨병신병환자균유감소뇨단백적작용,용약후6개월수방뇨단백무명현회승.
Objective To test the effect of prostaglandin E1 on proteinuria in the patients with diabetic nephropathy. Methods 81 patients with diabetic nephropathy were conducted into two groups. According to the excretion of urinary albumin and renal function, we evaluated the change of proteinuria for 3 subgroups(early stage DN, clinical stage with normal and abnormal renal function). 45 patients were treated with intravenous infusion of 10 μg Lipo PGE1 per day for 14 days. Among them, 16 patients were with early diabetic nephropathy and 29 patients with clinical diabetic nephropathy. 36 patients in control group. Results In treating group, proteinuria and albuminuria were significantly reduced as compared with the control group. In early stage DN, there was decreased proteinuria (0.21±0.07) g/24 h vs control (0.34±0.06) g/24 h and decreased albuminuria (99±53) mg/24 h vs control (191±76) mg/24 h, P <0.01). In clinical stage DN with normal renal function, proteinuria decreased (2.38±1.47) vs control (3.74±1.99) g/24 h, ( P <0.01) and albuminuria decreased (1 634±1 093) vs control (2 855±1 790) mg/24 h, ( P <0.01). In clinical stage DN with abnormal renal function, both proteinuria and albuminuria decreased (1.84±1.08) vs control (1.89±0.93) g/24 h( P >0.05) and (1 116±557) vs control (1 407±835) mg/24 h( P < 0.05 ) separately. Conclusion The administration of prostaglandin E1 may decrease proteinuria during distinct stages of diabetic nephropathy and these results did not change in last 6 month.
